Your AI-Trained Oncology Knowledge Connection!
Panelists discuss how sequential therapy selection for patients with HER2+ breast cancer with progressive brain metastases requires careful consideration of prior treatments, patterns of progression, symptom burden, and available clinical trials, while balancing the need for both systemic disease control and CNS -specific approaches.
Panelists discuss how the DESTINY-Breast12 trial evaluated trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer (mBC) with brain metastases, demonstrating encouraging intracranial responses and overall survival outcomes while maintaining a manageable safety profile consistent with previous T-DXd studies.
Panelists discuss how treatment selection for patients with HER2+ breast cancer with brain metastases requires careful consideration of factors such as metastatic burden, symptomatology, and prior therapies, typically incorporating both local approaches and systemic agents with CNS activity while accounting for individual patient characteristics such as performance status, comorbidities, and preferences in developing personalized treatment plans.
Panelists discuss how patients with HER2+ breast cancer frequently develop brain metastases, with recent pivotal trials such as HER2CLIMB and DESTINY-Breast03 demonstrating improved intracranial responses with newer agents such as tucatinib, and how trastuzumab deruxtecan leads to evolving standards of care (SOC) that now incorporate these targeted therapies alongside traditional local therapies.
Panelists discuss how trastuzumab deruxtecan’s (T-DXd's) key adverse events (AEs) include interstitial lung disease, neutropenia, and nausea/fatigue, emphasizing the importance of proactive monitoring, early intervention through coordinated multidisciplinary care, and comprehensive patient education with clear communication channels for reporting symptoms.
Panelists discuss how trastuzumab deruxtecan (T-DXd) demonstrated favorable patient-reported outcomes and quality of life measures in HER2-low hormone receptor-positive metastatic breast cancer patients in DESTINY-Breast06, suggesting it could be a well-tolerated therapeutic option that maintains patients' daily functioning while providing clinical benefit.
Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences.
Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.
Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates.
Panelists discuss how evolving HER2 classification methods and recent trial data are reshaping treatment approaches for advanced breast cancer, particularly regarding the clinical significance of HER2-low and ultralow categories.
Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss novel agents in the pipeline for patients with advanced HER2-positive breast cancer.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss how to decide on treatment for patients with advanced or metastatic HER2-positive breast cancer who have central nervous system metastases.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the prognosis for patients with advanced or metastatic HER2-positive breast cancer.
Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.
Dr. Neil M. Iyengar closes the discussion with preliminary results from a phase I study, thoughts on use of biosimilars, and other in-progress trials of interest.
Clinically relevant advice for the monitoring and management of pulmonary complications in patients with HER2+ mBC.
Discussion centered around the latest data and guideline updates, and how these changes affect therapy sequencing in the first, second, and third lines of treatment.
Insights concerning the selection of effective treatment approaches for patients with HER2+ mBC presenting with brain metastases and other complications.
An expert breast medical oncologist discusses recent changes to HER2+ mBC treatment guidelines due to key findings from the DESTINY-Breast03 trial.
Neil M. Iyengar, MD briefly reviews the standard-of-care first-line treatment for patients with metastatic HER2+ breast cancer as well as historical approaches to progression after first-line treatment.
A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.
Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.
Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.
Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.
Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.
Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.
Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.
